Leveraging biosimilars to drive savings and support patient access

By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.

July 01, 24

Evernorth chief bullish on driving affordability through biosimilars and access through guided care

May 08, 24

Outcomes 2024: How Evernorth manages the drug pipeline today and prepares for tomorrow

May 08, 24

Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June

April 25, 24

Enhancing health outcomes and savings through value-based solutions

Patient engagement paired with cost-containment strategies drives better health outcomes and reduces the financial burden for plan sponsors.

Kasey Raetz, PharmD, April 15, 24

Express Scripts in 2023: Supporting clients, patients, and health plans

Over the last 12 months, Express Scripts has rolled out numerous groundbreaking programs and projects. Learn about some of the most notable advancements and innovations of 2023.

December 19, 23